What is HC Wainwright’s Estimate for CADL FY2026 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 earnings estimates for Candel Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($1.19) for the year, up from their prior estimate of ($1.28). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.33) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($0.89) EPS, FY2029 earnings at $0.60 EPS and FY2030 earnings at $1.31 EPS.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06.

Several other equities analysts have also recently issued reports on the company. Zacks Research cut Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Bank of America raised Candel Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $12.00 to $18.00 in a report on Monday, September 21st. Citigroup dropped their price target on Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a research report on Monday. Jefferies Financial Group initiated coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They set a “buy” rating and a $25.00 price target for the company. Finally, UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Candel Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.29.

Read Our Latest Analysis on CADL

Candel Therapeutics Stock Performance

CADL opened at $5.81 on Tuesday. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $14.00. The stock has a market cap of $444.58 million, a P/E ratio of -3.93 and a beta of -0.27. The stock’s 50 day simple moving average is $9.61 and its 200 day simple moving average is $8.39. The company has a debt-to-equity ratio of 0.38, a current ratio of 16.09 and a quick ratio of 16.09.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Candel Therapeutics during the 3rd quarter worth approximately $41,000. Renaissance Technologies LLC acquired a new stake in Candel Therapeutics during the 1st quarter valued at $63,000. Legal & General Group Plc acquired a new stake in Candel Therapeutics during the 2nd quarter valued at $63,000. Cetera Investment Advisers purchased a new position in Candel Therapeutics during the third quarter worth $124,000. Finally, Janney Montgomery Scott LLC increased its position in Candel Therapeutics by 12.6% during the first quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock worth $149,000 after buying an additional 3,400 shares in the last quarter. 13.93% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Candel Therapeutics

These are some of the CADL headlines that stood out recently:

  • Positive Sentiment: A Seeking Alpha article describes an upgrade despite the filing delay, suggesting some investors see potential beyond the near-term setback. Seeking Alpha article
  • Negative Sentiment: Candel pushed the aglatimagene BLA submission to mid-2027. The delay followed earlier statements about filing timing and came after the company raised $80 million partly to prepare the application, prompting a sharp selloff and continued pressure on the shares. The Pharma Letter article
  • Negative Sentiment: Levi & Korsinsky and Hagens Berman have announced investigations into whether Candel’s statements about the BLA timeline violated securities laws. These are allegations under investigation, not findings of wrongdoing, but add legal uncertainty. Levi & Korsinsky investigation notice

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Read More

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.